On the Sunday night before the 2014 JP Morgan Healthcare conference, Intercept Pharmaceuticals, Inc. was the talk of the town in the bars around San Francisco. This was because of its recently announced positive results for obeticholic acid (OCA) in non-alcoholic steatohepatitis (NASH). Six years later, the FDA has issued a complete response letter (CRL) for OCA in NASH amid consternation on OCA’s safety, efficacy, surrogate endpoints and the real number of NASH patients.
That 2014 JP Morgan conference was Intercept’s coming-out party. The announcement of the positive results from an interim analysis of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?